A Novel Replication-Competent Vaccinia Vector MVTT Is Superior to MVA for Inducing High Levels of Neutralizing Antibody via Mucosal Vaccination

Xiaoxing Huang, Bin Lu, Wenbo Yu et al. · 2009

Read A Novel Replication-Competent Vaccinia Vector MVTT Is Superior to MVA for Inducing High Levels of Neutralizing Antibody via Mucosal Vaccination by Xiaoxing Huang, Bin Lu, Wenbo Yu et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0004180.txt.

Description

Xiaoxing Huang and colleagues published this vaccine study in PLOS ONE in 2009. Vaccines given through mucosal surfaces, such as the nose or mouth, can block viruses where they first enter the body. The team compared two vaccinia-based vectors head to head: MVA, a well-known weakened strain, and MVTT, a novel version that can still copy itself.

They measured the neutralising antibody levels each vector produced after mucosal vaccination. They report that MVTT was superior to MVA, inducing higher levels of these virus-blocking antibodies. The comparison informs the design of vaccines delivered without needles.

Catalog record

CREATORXiaoxing Huang, Bin Lu, Wenbo Yu et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004180

Browse the full library · About the Tower of Babel